Reply to Pirus Ghadjar and Thomas Wiegel's Letter to the Editor re: Abdenour Nabid, Nathalie Carrier, André-Guy Martin, et al. Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial. Eur Urol 2018;74:432-31

Affiliations

¹ Radiation Oncology, Centre Hospitaler Universitaire de Sherbrooke, Sherbrooke, Canada. Electronic address: abdenour.nabid@usherbrooke.ca.
² McGill University Health Centre, Montreal, Canada.

Comment

Abdenour Nabid et al. Eur Urol. 2019 Mar.

. 2019 Mar;75(3):e63.

doi: 10.1016/j.eururo.2018.10.029. Epub 2018 Oct 26.

¹ Radiation Oncology, Centre Hospitaler Universitaire de Sherbrooke, Sherbrooke, Canada. Electronic address: abdenour.nabid@usherbrooke.ca.
² McGill University Health Centre, Montreal, Canada.

No abstract available

Comment on

Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial.
Nabid A, Carrier N, Martin AG, Bahary JP, Lemaire C, Vass S, Bahoric B, Archambault R, Vincent F, Bettahar R, Duclos M, Garant MP, Souhami L. Nabid A, et al. Eur Urol. 2018 Oct;74(4):432-441. doi: 10.1016/j.eururo.2018.06.018. Epub 2018 Jul 3. Eur Urol. 2018. PMID: 29980331 Clinical Trial.
Re: Abdenour Nabid, Nathalie Carrier, André-Guy Martin, et al. Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial. Eur Urol 2018;74:432-31.
Ghadjar P, Wiegel T. Ghadjar P, et al. Eur Urol. 2019 Mar;75(3):e61-e62. doi: 10.1016/j.eururo.2018.10.030. Epub 2018 Oct 26. Eur Urol. 2019. PMID: 30670365 No abstract available.